LifeMD, Inc.

Good afternoon. Thank you for joining us today to discuss the results for LIFE-MD's fourth quarter and year-ended December 31, 2021. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer, and Mark Benison, Chief Financial Officer of LIFE-MD. Following management's prepared remarks, we will open the call for a question and answer session. I'd like to remind everyone that today's call is being hosted via webcast, and the recording will be made available via the link in today's press release. which is available in the Investor Relations section of the company's website. Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements, which are subject to numerous risks and uncertainties that may cause the company's actual results to differ materially from those rejected. These risks and uncertainties are described in the company's 10-K and 10-Q filings and within other filings that LifeMD may make with the SEC from time to time. Forelinking statements made during this call are based on current information available to the company as of today, March 7, 2022. The company assumes no obligation to update or revise any forelinking statements after today's call, except as required by law. Also, please note that the management will be discussing certain non-GAAP financial measures that the company believes are important in evaluating LifeMD's performance. Details on the relationship between these non-GAAP measures to the most Comparable gap measures and reconciliations thereof can be found in the press release issued earlier today. Finally, I would like to remind everyone that today's call is being recorded and will be available for replay in the Investor Relations section of the company's website. Now, I'd like to turn the call over to LifeMD's CEO, Justin Scriber.

Please go ahead.

Thank you, Operator, and good afternoon, everyone. Thank you for joining us today to discuss our fourth quarter and year-end 2021 results. 2021 was another year of outstanding achievement for LifeMD. Numerous accomplishments throughout the company characterized 2021 for us, including triple-digit growth in revenues across both our telehealth and Work Simply segments, record growth in new patient subscribers, the launch of our teledermatology brand for women, NAVA, the beta launch of our virtual primary care platform, and the successful completion of a financing transaction that we believe will capitalize LifeMD permanently to achieve profitability and the fulfillment of our mission to change healthcare. Our revenues, which we pre-announced in January, were up 149% over the previous year to a record $93 million for the full year. All of our performance metrics underlying our record-breaking year were strong as well. Gross margins, average daily rate of new subscriber acquisitions, customer acquisition costs, revenue from rebills of existing patient subscribers, and subscription revenue as a percent of total revenue all achieved record levels of performance in 2021. Of note, during a year when media rates rose exponentially versus 2020, our team was able to successfully drive a 23% reduction in customer acquisition costs, while also achieving the aforementioned record performance in top line growth metrics and new patient signups. I believe these record achievements encapsulate the LifeMD difference, our superior ability to efficiently and effectively attract and retain patient subscribers in a variety of consumer and advertising market conditions. As we recently outlined in our first annual Investor and Analyst Day in February, we remain focused on our pursuit of aggressive long-term growth in revenue and rapid expansion of our operating margins with the goal of attaining $250 to $300 million in net revenues by 2025 with at least 25% adjusted EBITDA margins. In addition to the continued strong growth and performance of our core lifestyle-oriented healthcare brands, Rex, Shapiro, and Nava, We are equally excited about the newest additions to the LifeMD telehealth platform, Cleared, and our virtual primary care service, LifeMD. Primary Care and Cleared, along with our lifestyle-oriented brands, will synergistically help us empower patients to live healthier lives by giving them access to affordable and comprehensive personalized healthcare. In January of this year, LifeMD announced the first acquisition in the company's history when we closed in the acquisition of Cleared Technologies, a leading allergy, asthma, and immunology telehealth clinic. Not only does this business represent a tremendous jumping off point into a very large and pervasive market as one in three American adults suffer from allergies or asthma, it is also highly synergistic with the existing LifeMD platform. In addition to the tremendous opportunity to scale Clear's direct-to-patient offering by leveraging LifeMD's proven capabilities, following the acquisition of Clear, we've begun to expand LifeMD's business model even further through direct partnerships with pharmaceutical companies. Under these initial agreements, we will use our tremendous healthcare advertising and patient retention capabilities to partner directly with pharmaceutical companies and manage these activities in a highly efficient, effective, and compliant manner. We believe this is an important stepping stone in the continued evolution of our business, exploiting the strength of our core competencies. We followed up the announcement of the cleared acquisition with a nationwide launch of Life&V's virtual primary care platform following the successful beta launch. Our primary care platform anchored by our comprehensive 50 state affiliated medical group and seamless proprietary technology platform aims to disrupt the market with a convenient patient first and frictionless experience in primary care at a highly affordable price point leading to better outcomes for patients. As we demoed at our recent investor day, our platform not only features a seamless one-stop shop technology platform, It also integrates with leading nationwide partners, including Quest Diagnostics, Axel Health, and Prescriptive, to provide our members with best-in-class lab work, diagnostics, in-home services, and prescription drug discounts. As we begin to scale this business, we see not only tremendous opportunity to cross-sell this offering to the more than 500,000 patients LifeMD's affiliated medical group has treated to date, and 1,000-plus new patients onboarded each day, but also to the millions of Americans who are either uninsured, underinsured, have high deductible health plans, or who simply lack access to quality medical care. The LifeMD platform provides comprehensive one-on-one relationships with high-quality doctors in primary care medicine and in an ever-growing range of specialties. We provide direct contact with doctors when and where patients need it, quick responses to their questions, and access to their medical histories, all at pricing that is affordable and transparent. With that, I will now turn the call over to our CFO, Mark Benison, who will provide a summary of our financial results. Mark?